Podcasts about laplace

Et si le futur n'était pas prédéterminé ? Cette vidéo plonge dans les mystères de la physique quantique pour explorer une vérité fascinante : le hasard pourrait être une composante fondamentale de la réalité. Du déterminisme classique du démon de Laplace à la révolution provoquée par l'intrication quantique et les expériences d'Alain Aspect, découvrez comment la science a révélé que certaines décisions de l'univers sont fondamentalement imprévisibles.La mécanique quantique, à travers le principe d'incertitude d'Heisenberg, la superposition des états et l'effondrement de la fonction d'onde, remet en cause l'idée même d'un avenir écrit à l'avance. Ce hasard irréductible n'est pas une imperfection : il est ce qui permet à l'univers d'évoluer librement, de se réinventer sans cesse.

C'est la libre-antenne du dimanche midi ! Attablez-vous et venez débattre avec la joyeuse bande de Stephen Brun tous les dimanches entre 13h00 et 15h00. Durant deux heures, les auditeurs sont au cœur de l'émission pour échanger avec Stephen Brun, Alexandre Biggerstaff, Maxime Pauty, Erwan Abautret et tous leurs invités.

durée : 00:06:16 - Bertrand Masson, adjoint à la Culture à la mairie de Nancy - La 47e édition du Livre sur la Place s'ouvre ce vendredi matin. 175 000 visiteurs attendus. Plus de 500 auteurs. POur en parler, nous recevions, ce vendredi, à 7 h 45 Bertrand Masson, Adjoint à la culture à la mairie de Nancy. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

durée : 00:03:06 - Guillaume Gallienne président du Livre sur la Place Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Host Dr. Shannon Westin and guest Dr. Hani Babiker discuss the JCO article "Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." TRANSCRIPT TTFields in Locally Advanced Pancreatic Adenocarcinoma Dr. Shannon Westin: Hello everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth with manuscripts that have been published in the Journal of Clinical Oncology. I am your host, gynecologic oncologist Shannon Westin, social media editor at the JCO, and just excited to be here to learn today about pancreatic cancer. None of our participants have conflicts of interest related to this podcast, and it is my honor to introduce Dr. Hani Babiker. He is an associate professor of medicine, consultant in oncology at the Mayo Clinic in Jacksonville, Florida. Welcome, Dr. Babiker. Dr. Hani Babiker: Hi, Dr. Westin. Thank you for the great opportunity to discuss our trial, and thank you for having me here. I really appreciate it, and I am excited. Dr. Shannon Westin: All right, so are we. So we are going to be talking about “Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: A Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.” This was simultaneously published and presented in the JCO and at the annual meeting of ASCO on 5/31/2025. So, let's level set. Can you speak to us just a little bit about pancreatic cancer? What is the survival, and what is the typical treatment for locally advanced disease? This gynecologic oncologist has not kept up in this field. Dr. Hani Babiker: Absolutely, Dr. Westin, and thank you for that question. Pancreatic adenocarcinoma is a lethal cancer. When I first started my career, the 5-year survival, per the Surveillance, Epidemiology, and End Results, was at 4.5%. I always, whenever I was giving talks, say that I really hope that I will see it in the double digit. Now, the 5-year survival for all pancreatic adenocarcinoma is 13.3%. And the 5-year survival, and although it is a double digit, I still hope that I will see it in a higher double digit in the future. It is even worse in patients with metastatic cancer, about 3% 5-year survival for metastatic pancreatic cancer. It is a dismal diagnosis. I really hope in the future we will find a better therapeutic approach to this lethal cancer. Dr. Shannon Westin: Yes, I just lost a very dear friend and colleague to this disease, so I completely agree with you. Well, now that we are settled kind of with the basics here, I would love to talk a little bit about kind of the primary piece of this intervention, the Tumor Treating Fields. So, how does this work? And what diseases has it gotten indications in as yet? Dr. Hani Babiker: Absolutely. So, Tumor Treating Fields is alternating frequency electrical fields that have been studied preclinically and shown that it abrogates cancer cell proliferation. Earlier on, we knew that it inhibits polymerization of tubulin, and hence, it affects cancer cells from proliferating. Later, we are learning that there are multiple mechanisms of action. It affects permeability, allowing for better drug delivery. It also inhibits cancer cell proliferation through affecting autophagy mechanisms that pancreatic cancer cells will use for proliferating and becoming more aggressive. There is also some early data preclinically in colorectal cancer cell lines and lung cancer cell lines and in vivo models showing that it potentially could activate the microenvironment to make it more pro-immunogenic. We recently published papers showing that it could also affect the nanomechanical properties of the tumor microenvironment within pancreatic cancer, hinting towards affecting, potentially, the stroma. So, there are multiple mechanisms to Tumor Treating Electric Fields. It is a new, novel therapeutic approach. Sometimes when I speak with my trainees, I say, "Well, we have surgery, we have radiation and chemotherapy, and this is something new." Tumor Treating Fields initially was studied in refractory GBM and got an indication there. Subsequently, frontline treatment of GBM in a randomized clinical trial, and then malignant pleural mesothelioma and non-small cell lung cancer. We have studied it in pancreatic cancer. Dr. Shannon Westin: I don't think I have ever heard it described so perfectly. That was brilliant. So thank you, and I hope everyone listening knows that you just got a masterclass on this mechanism. You know, they dabbled in it a little bit in ovarian cancer and it didn't quite make the grade, so I was a little definitely disappointed. But very excited about the data we're going to talk about today. So let's get into the PANOVA-3 study. Can you highlight the overall design and also the key eligibility criteria that would be helpful for our listeners? Dr. Hani Babiker: Absolutely. So, it started off with preclinical work in pancreatic cancer showing Tumor Treating Fields with chemo abrogate cancer cell perforation. It led to a trial, the PANOVA-2 trial, that was run in Europe that showed efficacy for OS and PFS in patients with locally advanced pancreatic cancer, which included metastatic and locally advanced pancreatic cancer, more so in locally advanced that led to the PANOVA-3 trial, which was an international, global study. This was in more than 190 centers, 20 countries in Latin America, North America, Europe, and Asia. It was a randomized trial. Patients were randomized 1 to 1 to either chemotherapy with gemcitabine plus nab-paclitaxel per drug label. The other arm was with Tumor Treating Fields at 150 kHz for a recommendation for patients to wear it 18 hours per day. The primary end point of the trial was OS, overall survival. The secondary end point included other efficacy landmarks such as local PFS, pain control, quality of life, and safety. And there was a post hoc that looked at distant PFS. Dr. Shannon Westin: That's a pretty common secondary end point in pancreatic studies of looking at the pain-free interval. I thought that was really brilliant because, you know, I think in gyn cancers, we see resolution of symptoms as being a really big deal, but it's not necessarily something that we always look at. So I thought that was really nice that you included that. Okay, talk to us a little bit about the population. So, the population that actually got treated in PANOVA-3 is pretty generalizable to what people are treating in the clinic. Dr. Hani Babiker: So, in pancreatic cancer, unfortunately, most of our patients present, approximately 80%, with metastatic disease. Local is divided to resectable, borderline, and locally advanced. We studied this trial, a randomized trial, in locally advanced and unresectable, which is really an unmet need. Most of our patients with locally advanced and unresectable are grouped up with other trials in the metastatic setting without a focus on locally advanced and unresectable, save for a few trials. This year, a trial that we were looking for for a long time, the LAPLACE trial, unfortunately, that we were very excited about, this is a molecule that targeted connective tissue growth factor, that showed earlier efficacy in a randomized trial, did not meet up the median OS end point. And hence, PANOVA-3 is the first trial in locally advanced and unresectable that did meet its primary end point. So, it's a very unmet need in locally advanced and unresectable. A lot of the times, our patients in clinic are treated with frontline chemotherapy that was studied in metastatic disease and locally advanced and unresectable, which include either FOLFIRINOX, NALIRIFOX, or gemcitabine/abraxane. I do have in my clinic multiple patients that would stay on the regimen for such a long time, and then we would have to devise a mechanism of maintenance, although this is not studied really in details, either with capecitabine or dropping the oxaliplatin to continue FOLFIRI. And then we also approach chemoradiotherapy. So the trial was in a disease in pancreatic cancer that really is an unmet need. So the inclusion criteria included a patient with locally advanced and unresectable. These were done at multiple centers. Most of them academic centers were discussed at the tumor board, and if it's unresectable, they will be meeting specific metrics of appropriate liver function tests, kidney function tests, and blood counts. We excluded patients that obviously had, given that these are electric fields, patients that have, for example, stimulators or pacemakers, knowing that this could potentially affect some of these devices. But for the most part, it was locally advanced and unresectable patients with a very good performance status and good counts. Dr. Shannon Westin: That's great. I think everyone's excited to hear about the primary outcome of overall survival. What did you find, and how does it compare to some of the recent trials? Dr. Hani Babiker: We're very excited that it did meet its primary end point of median overall survival. It was very exciting knowing that a lot of us were disappointed a little bit of some of the trials that were presented at ASCO GI, such as the LAPLACE trial that I alluded to. Just before the presentation, the PRODIGE 29 trial that is in locally advanced and unresectable that randomized patients with locally advanced disease to either FOLFIRINOX or single-agent gemcitabine, allowing for a crossover, although it did meet its primary end point of PFS, there was no overall survival benefit. So that kind of got us a little bit disappointed, but having the PANOVA-3 trial being positive in median OS got us all excited. In addition, the 12-year overall survival rate was increased in both the intention-to-treat and modified intention-to-treat. The modified intention-to-treat were patients that have had at least one cycle of therapy with TTFields daily and/or one cycle with chemotherapy, which was gemcitabine plus nab-paclitaxel. There was a trend to improvement in PFS and local PFS, although that did not have statistical significance, but the 12-year PFS rate in both the intention-to-treat and modified intention-to-treat was significant. For me, as one of the investigators, that told me that there might be a specific biomarker that would tell me that patients could respond greater than others, more exceptional than others, given that 12-month PFS rate was improved. On a post hoc analysis, the distant PFS was improved with the intervention of Tumor Treating Fields with gemcitabine plus nab-paclitaxel. In addition, there was an improvement in global health status and quality of life in addition to pain-free survival, which is a strong hurdle in our patients with pancreatic adenocarcinoma that most present with significant abdominal pain. Dr. Shannon Westin: One of the other questions that I think has come up is around central review. So did you all use central review in this study? Dr. Hani Babiker: Most of the centers were academic centers. These were discussed in tumor boards, which included radiation oncologists and surgeons. I wanted to point out that it's very important to note that the primary end point was overall survival. So the primary end point was not PFS. Hence, the central review would help us, for example, with elaborating and making sure patients were actually locally advanced disease, but in a setting where the primary end point is overall survival, that was the key point of the clinical trial. This trial was discussed at academic centers, and all included tumor boards to decide if patients were locally advanced or not. In the trial, there was a good proportion of patients, or percentage, that had a CA 19-9 more than 1000. That could indicate that potentially there are a fraction of patients that actually had metastatic disease, micrometastatic disease. So that could hint towards why the median OS was slightly lower then in both arms when compared to, for example, the trial that was presented at ASCO GI, the LAPLACE trial. However, having said that, we were very excited about the trial. It was the first positive trial in locally advanced and unresectable to meet median OS survival. Dr. Shannon Westin: It's so awesome. So congratulations. Okay, so let's talk a little bit about your very detailed secondary end points because you had a lot of really prudent choices there. So anything that was interesting or informative in those end points? Dr. Hani Babiker: One major hurdle back we have for most of our patients with pancreatic adenocarcinoma, like I mentioned earlier, is pain. We try to approach it, obviously, with narcotics. If it doesn't work, we try to do celiac axis block interventionally, and that sometimes is successful and sometimes is not. So actually, to see the pain-free survival end point to be met was very exciting for us. And as for me, as a scientist that studies TTFields in clinic and lab as also to develop a mechanism and understanding really how that works. That was very important for us that in addition to chemotherapy, it improved pain-free survival or deterioration of pain. And most importantly, our patients with pancreatic cancer, this disease is very aggressive. It affects quality of life of patients. Patients feel fatigued, tired. It's a procoagulant tumor that causes clots and strokes, etcetera, marantic endocarditis. And one big problem we deal with when we're seeing patients in clinic is obviously that quality of life. Although data have shown with treatment, with frontline regimens, that quality of life improves with treatment and chemotherapy, it's actually great to see that that improvement happens early in addition to Tumor Treating Fields. The other interesting point was that it was not only pain and quality of life, but also digestive symptoms that are improved with this intervention, knowing that a lot of our patients do have pancreatic cancer, pancreatic exocrine insufficiency that affect also with digestion, and a lot of our patients have abdominal pain after eating and diarrhea. So it was interesting to see that also improved with the intervention. Dr. Shannon Westin: You have touched a little bit on some of the adverse events, kind of with the TT mechanisms, but I'd love to hear a little bit more detail around adverse events in general in this study, as well as specific AEs related to the Tumor Treating Fields. Dr. Hani Babiker: Absolutely. So when we compared both arms, there was a similar toxicity related to the regimen, mostly with chemotherapy, but in specifically to Tumor Treating Fields, there was a rash, and that included dermatitis and rash. Most of the side effects were grade 1 and grade 2. Grade 3 toxicities related to skin was less than 10%, approximately 7% to 8%, and hence did not affect many patients. But it was something to note, and it's something that in the future, when we develop a mechanism of treating patients to note early. We in our clinic have learned to treat patients in the clinical trial early with topical steroids to each patient, of shifting the arrays to mitigate some toxicity and rash. We do advise our patients in hot areas, we keep them aware that sweating, for example, can lead to higher conductivity of electrical fields with a predisposition for rash. So if there's an opportunity to stay in a little bit of a cold area, make sure that the arrays are shifted, use topical steroids early. If it's a significant rash, to hold treatment for at least 48 hours and speak to the investigators. And through these mechanisms, we have learned that we were able to mitigate the rash quite a bit. Dr. Shannon Westin: That's awesome. Thank you so much. Yeah, I'm, it's summer right now, and I think- I'm in Texas, you're in Florida, like we know. Okay, so I guess, again, you have been kind of touching on this, but I would love to know, like if in the quality-of-life assessments or if just in your discussions with patients, like how easy is this to use? How easy is the Tumor Treating Fields device to use, and what do patients really think? Dr. Hani Babiker: Absolutely. We have learned that whenever we speak with patients, it's always good to discuss with them briefly the science of it. A lot of patients would want to know if it's interventional, is that something that goes, is delivered percutaneously or not, and we explain that these are delivered through arrays that are through the skin. We always touch base with them about a lot of question I get about mechanism of action and then about compliance. So I think one important thing to note is that compliance with the use of the device is a lot of the question we'll get quite a bit. Patients know there's going to take an effort from them, and some of my patients enjoyed it because they felt like they also are fighting the disease by wearing the device. I have learned very quickly that having a team, surrounded by a team that knew how to mitigate some of the side effects and knew how to explain how to use the device helped quite a bit. And this included some of our nurses and our nurse practitioners and our clinical research coordinators who've done a wonderful job of showing these arrays actually to patients before they start on the trial, look at it, know how it works. The other point to know is that the sponsor provided Device Support Specialist, we call them DSS, they have been instrumental in helping us, helping the patients know how to use the device, how to use the generator, how to change the batteries, and that helped us conduct the trials and enroll very well. I would envision in the future with education and relying on the Device Support Specialist and having a team that knows how to use the device and mitigate some of the side effects will go a long way for patients to learn about this treatment. Many of the times our patients said while they are on the clinical trial felt like they are also being part of this team in applying the device and fighting the cancer. Dr. Shannon Westin: That's awesome. Well, I guess the bottom line. Is it ready for prime time? Is this something you are going to use for your patients in the clinic? Dr. Hani Babiker: Absolutely. In a disease that has poor prognosis, and we are trying our best to find new treatments to fight this cancer and treatment modalities, presenting patients with all the treatment options that are out there would be recommended. It's what I would do it for in my clinic. And you know, it's funny that I am mentioning that right now. I had a patient who was seen internationally asking about the trial and the device and had locally advanced and unresectable before they start frontline treatment. I do think that there is going to be an educational piece. Obviously, this is not a pill, it's not an intravenous chemotherapy that we're very well and accustomed to. And some of us in academic centers know it very well. I usually joke that whenever I am talking about it in pancreatic cancer, if there is a radiation oncologist in the room, they will be like, "Yeah, we know all about it. We have been treating patients with GBM over there." So a lot of the times, when we first went to trial, if I had any questions, I would call them and ask them. So from their perspective, they, because they use it as a standard of care in treatment of GBM, they develop significant expertise in it. I think in the GI world, specifically and with oncologists that treat pancreatic cancer and specifically oncologists in the community, learning about the device and how to use it, how to recommend it, how to mitigate side effects, will be hopefully for prime time in the future. Dr. Shannon Westin: That's great. Sounds like some real educational opportunities there. Well, this has been awesome. Thank you so much, Dr. Babiker. I mean, I learned a ton, and I wish that we could find a way to use this in gynecologic cancers, but really, really just want to commend you on the design of the trial and the success in this really devastating disease. So again, this was "Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: A Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." And as always, I am your host, Shannon Westin. Please go check out our other offerings wherever you get your podcasts and have an awesome day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Dr. Babiker Disclosures Consulting or Advisory Role: Endocyte, Celgene, Idera, Myovant Sciences, Novocure, Ipsen, Caris MPI, Incyte, Guardant Health Speakers' Bureau: Guardant Health Research Funding:  Spirita Oncology, Novocure, AstraZeneca, JSI, Incyte, Qurient, HiFiBiO Therapeutics, Revolution Health Care, Elevation Oncology, Dragonfly Therapeutics, Zelbio, BMS, Mirati Therapeutics, Strategia        

Chaque jour, écoutez le Best-of de l'Afterfoot, sur RMC la radio du Sport !

Aujourd'hui, Fatima Aït Bounoua, Didier Giraud et Bruno Poncet débattent de l'actualité autour d'Alain Marschall et Olivier Truchot.

In this episode of the Weekly Wine Report on the Vint Wine Podcast, host Billy Galanko blends current events with wine history to give listeners both context and discovery. From La Place de Bordeaux's unique distribution system to the famous wines of Ancient Rome, you'll come away with new insights into how wine connects the present with the past.Highlights:A quick update on the Napa Valley Picket Fire and its impact on the 2025 harvest.An explainer on La Place de Bordeaux, how it works and why top estates outside Bordeaux, from Napa to Chile to Tuscany, release through it.Highlights from the September Beyond Bordeaux releases, including Opus One, Seña, Clos Apalta, Solaia, Penfolds Grange, Vin de Constance, and more.A look at famous ancient Roman wines, from Falernum and Pucinum to the enduring legacy of Malvasia.Whether you're a collector, sommelier, or simply curious about wine's global reach and deep history, this episode offers timely updates and timeless stories from across the wine world.

Chaque jour, retrouvez le journal de 8h de la rédaction d'Europe 1 pour faire le tour de l'actu. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Chaque jour, retrouvez le journal de 8h de la rédaction d'Europe 1 pour faire le tour de l'actu. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Chaque jour, retrouvez le journal de 8h de la rédaction d'Europe 1 pour faire le tour de l'actu. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Strasculture, c'est le grand rendez-vous de la rentrée à Strasbourg. La Place du Château se transforme en véritable village artistique : 120 structures sont présentes pour guider les habitants dans leurs loisirs et sorties. Associations, médiathèques, bibliobus, jeux et bons plans pour les jeunes rythment cette journée dédiée à la découverte culturelle.Reportage Tom Herga

Aujourd'hui, Yves Camdeborde, Joëlle Dago-Serry et Mourad Boudjellal débattent de l'actualité autour d'Alain Marschall et Olivier Truchot.

Legault veut s’attaquer à la bureaucratie. La liste des 32 projets priorisés par Mark Carney est maintenant connue. La rencontre politique avec Yasmine Abdelfadel et Mario Dumont. Regardez aussi cette discussion en vidéo via https://www.qub.ca/videos ou en vous abonnant à QUB télé : https://www.tvaplus.ca/qub ou sur la chaîne YouTube QUB https://www.youtube.com/@qub_radioPour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

Intéressé.e par notre formation Yaniro Leadership Program ? Prenez rendez-vous avec Yasmine ici !Voulez-vous former les managers avec la méthode do it yourself ? Obtenez toutes les ressources ici !Découvrez un extrait du podcast de Yaniro avec comme invité Florence Guémy qui a travaillé pendant 36 ans chez Bayard, une entreprise de médias qu'elle a récemment quittée après un parcours riche et varié.

Retrouve la vidéo et la transcription sur : https://www.francaisauthentique.com/arrete-de-trop-apprendre-fais-ca-a-la-place

L'été touche à sa fin, mais qui dit mois de septembre, dit : rentrée littéraire ! Parmi tous les livres que nous avons reçus cette année nous en avons sélectionné quelques uns dont nous voulions vous parler, entre coups de coeur, déception et bonnes surprises, la rentrée littéraire est riche en émotions ! PS : Un grand merci aux maisons d'édition qui ont nourri notre soif de découverte littéraire grâce à tous les livres que nous avons reçu cette année. Liste des livres de l'épisode : La bonne mère, de Mathilda Di Matteo (Editions L'Iconoclaste) Trois enterrements, de Anders Lustgarten (Editions Actes Sud) Mettre au monde, de Cloé Korman (Editions Flammarion) Nous sommes la voix de celles qui n'en ont plus, de Paola Guzzo et Cécile Rousset (Editions Actes Sud) Et aussi : Le podcast Vivons heureux avant la fin du monde - "Chacun son beauf : à quoi sert le mépris de classe" (Arte radio) La Place, Annie Ernaux L'Odyssée d'Hakim, Fabien Toulmé La série Years and Years, de Russell T. Davies Swept Away, de Beth O'Leary Carrie Soto is back, de Taylor Jenkins Reid Fun Girl, de Elizabeth Pich Watership Down, de James Sturm et Joe Sutphin d'après le roman de Richard Adams L'Assassin Royal, tome 2, de Robin Hobb Ils appellent ça l'amour, de Chloé Delaume Atmosphère, de Taylor Jenkins Reid Quand j'ai froid, de Valentine Choquet

Dans cet épisode, on plonge dans l'art de la communication et de la résolution de conflit. Comment exprimer ses besoins et ses limites sans blesser l'autre ? Comment rester aligné à ses valeurs quand la discussion devient intense ?Vous découvrirez des principes simples mais puissants pour aborder les conversations difficiles avec courage, clarté et bienveillance.

durée : 00:40:48 - Questions du soir : le débat - par : Quentin Lafay, Stéphanie Villeneuve - À quelques jours de la rentrée scolaire, Elisabeth Borne a annoncé mardi 26 août 2025, la mise en place d'une intelligence artificielle pour « accompagner les professeurs dans leur métier ». - invités : Giada Pistilli Philosophe spécialisée sur l'éthique de l'intelligence artificielle et éthicienne de l'IA chez Hugging Face; Christophe Cailleaux Professeur d'histoire-géographie dans un lycée de l'agglomération de Dijon, membre du groupe de réflexion du Snes sur le numérique, coordinateur du livre "Critiques de l'école numérique" (l'Échappée, 2019); Orianne Ledroit Déléguée générale de EdTech France, enseignante à Sciences Po Paris

durée : 00:40:48 - Questions du soir : le débat - par : Quentin Lafay, Stéphanie Villeneuve - À quelques jours de la rentrée scolaire, Elisabeth Borne a annoncé mardi 26 août 2025, la mise en place d'une intelligence artificielle pour "accompagner les professeurs dans leur métier". - invités : Giada Pistilli Philosophe spécialisée sur l'éthique de l'intelligence artificielle et éthicienne de l'IA chez Hugging Face; Christophe Cailleaux Professeur d'histoire-géographie dans un lycée de l'agglomération de Dijon, membre du groupe de réflexion du Snes sur le numérique, coordinateur du livre "Critiques de l'école numérique" (l'Échappée, 2019); Orianne Ledroit Déléguée générale de EdTech France, enseignante à Sciences Po Paris

Duke, Opuku, Ibrahim, Vrioni c'est un dénominateur commun. Pearce, Alvarez, JMR, Coccaro ça fait jaser. Prince Owusu c'est le temps d'en profiter pour le laisser partir?

'Les apôtres et les frères qui habitaient la Judée apprirent que les non-Juifs venaient d'accepter la Parole de Dieu. Et dès que Pierre fut de retour à Jérusalem, les croyants d'origine juive lui firent des reproches : Comment ! lui dirent-ils, tu es entré chez des incirconcis et tu as mangé avec eux ! Mais Pierre se mit à leur exposer, point par point, ce qui s'était passé. – Pendant mon séjour à Jaffa, dit-il, j'étais en train de prier, quand je suis tombé en extase et j'ai eu une vision : une sorte de grande toile, tenue aux quatre coins, est descendue du ciel et elle est venue tout près de moi. J'ai regardé attentivement ce qu'il y avait dedans et j'ai vu des quadrupèdes, des bêtes sauvages, des reptiles et des oiseaux. J'ai entendu alors une voix qui me disait : « Lève-toi, Pierre, tue ces bêtes et mange-les. » Mais j'ai répondu : « Oh ! non, Seigneur, car jamais de ma vie je n'ai rien mangé de souillé ou d'impur. » La voix céleste s'est fait entendre une deuxième fois : « Ce que Dieu a déclaré pur, ce n'est pas à toi de le considérer comme impur. » Cela est arrivé trois fois, puis tout a disparu dans le ciel. Et voilà qu'au même moment trois hommes sont arrivés à la maison où nous nous trouvions . Ils venaient de Césarée et avaient été envoyés vers moi. Alors l'Esprit me dit d'aller avec eux sans hésiter. Je pris donc avec moi les six frères que voici et nous nous sommes rendus chez cet homme. Celui-ci nous a raconté qu'un ange lui était apparu dans sa maison et lui avait dit : « Envoie quelqu'un à Jaffa pour faire venir chez toi Simon, surnommé Pierre. Il te dira comment toi et tous les tiens vous serez sauvés. » J'ai donc commencé à leur parler, quand l'Esprit Saint est descendu sur eux, de la même manière qu'il était descendu sur nous au commencement. Aussitôt, je me suis souvenu de cette parole du Seigneur : Jean a baptisé dans de l'eau, mais vous, vous serez baptisés dans le Saint-Esprit. Puisque Dieu leur a accordé le même don qu'à nous quand nous avons cru, qui étais-je, moi, pour pouvoir m'opposer à Dieu ? Ce récit les apaisa et ils louèrent Dieu et dirent : Dieu a aussi donné aux non-Juifs de changer pour recevoir la vie. ' Actes 11:1-18

durée : 00:02:49 - L'ailante, le faux ami qui prend toute la place - par : Nathalie Mazet Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Bienvenue dans le Jour 16 de notre série “30 jours pour préparer une rentrée à ton rythme”.Aujourd'hui, on parle d'un mot qu'on entend beaucoup mais qu'on oublie souvent d'appliquer : L'essentiel.Dans cet épisode, je t'invite à faire de la place pour ce qui compte vraiment.Et si cette rentrée était l'occasion pour toi de construire aussi une routine d'apprentissage ?Les cours Miftah ouvrent leurs portes.

durée : 00:03:31 - Le chantier de la place Clémenceau à pau s'adapte aux températures Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Le Savez-vous ? Nancy, c'est le podcast quotidien de l'Est Républicain consacré à la ville et à tout ce que vous ignorez sur elle.Un podcast raconté par Jean-Marie Russe basé sur les articles réalisés par la rédaction locale de Nancy. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Aujourd'hui, on passe à l'action !Pas de grand ménage, pas de mission impossible juste libérer un petit espace chez toi pour faire de la place aussi dans ton cœur et ton esprit.Dans cet épisode :– Pourquoi le désordre visuel fatigue ton cerveau– Comment créer un espace baraka chez toi– L'exercice simple du jour pour alléger ton mental

durée : 00:30:46 - Les Nuits de France Culture - par : Albane Penaranda - En 1971, Gilles Vigneault raconte ses débuts en France, l'enracinement populaire de la chanson au Québec et le rôle déterminant qu'elle a joué dans l'affirmation de l'identité québécoise, point de départ d'un large renouveau artistique. - réalisation : Emily Vallat - invités : Gilles Vigneault Poète, chanteur, auteur-compositeur

Depuis des milliers d'années, malgré l'exil qui nous a dispersés et la baisse de niveau spirituel d'une génération à l'autre, le Judaïsme authentique n'a pas disparu. Le Chabbath, les Téfilin et toutes les autres Mitsvot continuent d'exister et de nous concerner. Comment est-ce possible ?

durée : 00:38:52 - France Culture va plus loin (l'Invité(e) des Matins d'été) - par : Astrid de Villaines, Stéphanie Villeneuve, Sarah Masson -  La langue arabe, cinquième langue la plus parlée dans le monde, est mise à l'honneur au Festival d'Avignon, l'occasion de réfléchir à l'espace qu'elle occupe dans la société française, son enseignement, son héritage. Quelle place pour l'arabe en France ? - réalisation : Félicie Faugère - invités : Nada Yafi Interprète, diplomate française, traductrice; Nabil Wakim Journaliste au Monde et auteur

durée : 02:00:09 - Les Matins d'été - par : Astrid de Villaines, Stéphanie Villeneuve, Sarah Masson - . - réalisation : Félicie Faugère - invités : Véronique Nahoum-Grappe Anthropologue; Nada Yafi Interprète, diplomate française, traductrice; Nabil Wakim Journaliste au Monde et auteur; Reda Kateb Acteur de théâtre et de cinéma, réalisateur

REDIFF - Hervé Pouchol a la capacité de se trouver à plusieurs endroits en même temps ! Ou bien, est-ce son cousin Jean-Pierre qui a pris sa place dans l'émission ? Tout l'été, revivez les meilleurs fous rires, coup de gueule et débats de l'émission "Ça peut vous arriver" en podcast sur RTL.fr, l'application et toutes vos plateformes préférées.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Autrefois, le luxe se chuchotait. Il se transmettait dans le secret feutré des salons, se cachait derrière les rideaux épais d'un palace ou d'un vestiaire bien né. Aujourd'hui, il est partout — en story, en vitrine, en slogan, en NFT. Il habille nos imaginaires, investit nos désirs, colonise nos représentations. À force d'être brandi comme étendard, le voilà devenu quasi-synonyme de culture populaire. Une drôle de trajectoire pour un univers qui, il n'y a pas si longtemps, cultivait l'ombre, l'exclusivité et l'entre-soi..Pour comprendre comment le luxe est passé du territoire de l'exclusif à l'occupation permanente de l'espace symbolique, j'ai eu le plaisir de recevoir la journaliste Sophie Abriat, plume fine et acérée, collaboratrice de M Le Magazine du Monde et de T, le magazine du Temps..À l'occasion de la parution de son essai Danser sur le volcan (Editions Grasset), elle nous livre une réflexion vive et documentée sur une industrie qui vend bien plus que des vêtements : des récits, des valeurs, des affects. Une conversation qui interroge sans condamner, qui dévoile sans détruire, dans laquelle Sophie Abriat mêle sens critique et sensibilité, pour interroger ce que le luxe fait à nos imaginaires… et ce que nos imaginaires révèlent du monde. Retrouvez le podcast sur instagram : @decousupodcast, et bon épisode !

durée : 01:24:23 - Les Nuits de France Culture - par : Albane Penaranda - Les "Nuits magnétiques" proposaient en 1980 "La place des Abbesses", un documentaire signé par Nicole Bernheim, diffusé pour la première fois le 23 mai 1980. - réalisation : Milena Aellig

Its storm season in the Gulf South, and the National Hurricane Center has been tracking tropical disturbances headed towards the coast. Tropical Storm Barry formed over the weekend, and now forecasters are looking at more worrisome weather near Florida. Meteorologist Jennifer Narramore joins us to share an update and discuss how this year's hurricane season compares to previous ones.The Tony-award winning Sondheim musical “Company,” debuts at the Tulane Summer Lyric Theatre next weekend, July 10-13. The comedic performance is directed by Leslie Castay, a film and Broadway veteran with roots in LaPlace. She joins us with the details. It's been a rough year for the University of New Orleans. To close the school's deficit and start addressing its long-standing debt, administrators cut budgets, closed Milneburg Hall and laid off and furloughed employees. Now, the university is on its way to returning to the LSU System.Education reporter Aubri Juhasz tells us how two UNO employees, and members of its union chapter, are thinking about the school's future and what needs to change. __Today's episode of Louisiana Considered was hosted by Diane Mack. Our managing producer is Alana Schreiber and our assistant producer is Aubry Procell. Our engineer is Garrett Pittman.You can listen to Louisiana Considered Monday through Friday at noon and 7 p.m. It's available on Spotify, the NPR App, and wherever you get your podcasts. Louisiana Considered wants to hear from you! Please fill out our pitch line to let us know what kinds of story ideas you have for our show. And while you're at it, fill out our listener survey! We want to keep bringing you the kinds of conversations you'd like to listen to.Louisiana Considered is made possible with support from our listeners. Thank you!

POUR COMMANDER MON LIVRE : Sur Amazon : https://amzn.to/3ZMm4CY Sur Fnac.com : https://tidd.ly/4dWJZ8OExtrait de l'épisode PAUL WATZLAWICK - 10 conseils pour être malheureux PARTIE 2Cet épisode sera publié sur YouTube et en podcast vendredi prochain le 27 juinIl est d'ores et déjà disponible en intégralité sur ma page Patreon : https://www.patreon.com/posts/131054920---Envie d'aller plus loin ? Rejoignez-moi sur Patreon pour accéder à tout mon contenu supplémentaire.

Avec Natalie Saracco

Thierry Weber revient sur l'investissement de 400 millions de dollars de Microsoft en Suisse pour développer ses infrastructures cloud et IA. Une annonce stratégique, mais qui soulève des questions de souveraineté numérique : bien que les données soient stockées localement, elles restent soumises au droit américain via le Cloud Act. Alors que Microsoft s'impose dans l'écosystème helvétique, des initiatives locales peinent à rivaliser. Pour Weber, cet essor du cloud étranger est autant une opportunité de formation qu'un risque de dépendance numérique préoccupante.

ON S'ECHANGE QUOI A LA PLACE DES ALLIANCES ?Aujourd'hui, on inaugure un nouveau format d'épisode dans le podcast mariage ! Si tu te souviens bien, il y a quelque semaines,  je lançais le répondeur du podcast, avec ce premier message d'une future mariée @mathilde.yogifit : “Lorsqu'on s'échange déjà les alliances à la mairie, on s'échange quoi à la cérémonie, si on ne veut pas faire doublon ?”Alors, c'est parti, on va y répondre ensemble ! J'ai récupéré tous vos retours et j'ai organisé un peu les idées pour que cet épisode soit utile à toutes celles et ceux qui se posent la même question que Mathilde !L'important c'est de créer un instant à votre image, sincère, marquant, et émotionnellement fort. Bref, quelque chose qui VOUS ressemble pour marquer ce moment symbolique à votre manière.MERCI encore à toutes celles et ceux qui ont participé à cet épisode collaboratif, ça permet vraiment d'avoir des réponses variées ! Perso, j'adore ce format !! Si en écoutant ça, tu as des choses à ajouter, d'autres idées qui te viennent, n'hésite pas ! Viens me les partager, je pourrai ajouter d'autres inspirations pour compléter encore plus cet épisode.Et pour continuer sur ce format collaboratif, j'ai deux autres messages de mariées à te transmettre, écoute bien jusqu'à la fin, ça pourrait te concerner …*******Bienvenue DANS LA CONFIDENCE ! le podcast mariage qui aide les futures mariées tout au long de leurs préparatifs !Je suis Laurène, jeune mariée du 15 Juillet 2021, j'ai profité de l'année de report de mon mariage pour lancer ce podcast dédié aux futures mariées. Chaque Mercredi matin, je te donne RDV pour un nouvel épisode inédit ! Je reçois des jeunes mariées qui nous racontent tous leurs préparatifs jusqu'au déroulé de leur jour J. Et j'interviewe des professionnels du mariage pour décrypter au mieux les coulisses de leurs métiers et te faire découvrir des prestataires passionnés.Ce podcast mariage, c'est le meilleur moyen de faire le plein de conseils pratiques, de bons plans et de recommandations de prestataires ! Bref, tout ce dont on a besoin quand on prépare un mariage !*******Pour me contacter par mail : danslaconfidence.podcast@gmail.comRetrouvez toutes les infos de cet épisode sur le compte instagram du podcast  !Montage de cet épisode : Laurène GOLVANHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

durée : 00:59:45 - Entendez-vous l'éco ? - par : Aliette Hovine, Bruno Baradat - Connue pour ses scandales bancaires, la Suisse est aussi au cœur du mouvement de régulation bancaire en vigueur depuis la fin du 20e siècle. Comment le pays a-t-il construit son économie sur sa place financière, et que dit l'exemple suisse de l'histoire de la règlementation ? - réalisation : Françoise Le Floch - invités : Thibaud Giddey Historien, maître assistant en histoire à l'Université de Lausanne, chercheur postdoctoral à l'Université de Zürich; Thierry Philipponnat Economiste, fondateur et ancien chef économiste de l'ONG Finance Watch

On passe 90% de notre temps à l'intérieur. Autant dire qu'on a tous intérêt à s'y sentir bien. Et que l'on vive dans un studio ou une grande maison, on peut vite se sentir à l'étroit. Quand ça déborde, on empile, on entasse… et on étouffe. Sauf que parfois, ce n'est pas la taille du logement le problème, mais plutôt la manière dont on l'a organisé.  Le plus important c'est d'observer son quotidien. Où est-ce que vous accumulez ? Qu'est-ce qui traîne toujours ?  Si chaque logement est différent, chaque façon de vivre l'est aussi. Il faut donc adapter votre intérieur à vos véritables besoins. Côté meubles, quelles sont les astuces ? Et si on ne peut pas faire de travaux ? Ecoutez la suite de cet épisode de "Maintenant vous savez" Un podcast Bababam Orginals écrit et réalisé par Joanne Bourdin A écouter ensuite : À quoi sert la petite voix dans notre tête ? Comment lutter contre la procrastination avec la méthode du “task snacking” ? Qu'est-ce que la médecine quantique, cette arnaque qui envahit les réseaux sociaux ? Learn more about your ad choices. Visit megaphone.fm/adchoices

Djanii Alfa est artiste et activiste guinéen, devenu l'une des voix incontournables du hip-hop en Afrique de l'Ouest. Le 3 mai, il présentera à la Place, à Paris, son nouvel album Jour de paix. Un projet sur lequel il a réuni les artistes de la scène guinéenne Thiird, Limo ou encore Lalypop, ainsi que l'artiste burkinabè Smarty. Ibrahim Fama Diabaté, commissaire général du QITA (Quotient Intellectuel des Talents Artistiques), dont la 6ème édition aura lieu au Palais de la Culture, à Abidjan, le 24 mai. Et Serge Noukoué, co-fondateur du NollywoodWeek, film festival qui aura lieu du 7 au 11 mai au cinéma l'Arlequin, à Paris. Pour visionner les clips, cliquez sur les titres des chansons : Dadju x Tayc - Le contratTayc - Promets-le moiDjanii Alfa - Peace priceDjanii Alfa - Enfant soldatDjanii Alfa - Couleur afrik2pac feat Talent - Changes Marvin Gaye, Tammi Terrel - Ain't no mountain high enoughJocelyne Labylle - On verraRetrouvez notre playlist sur Deezer. 

Today we are joined by philosopher Jennifer Nagel for a take-no-prisoners look at universal skepticism—philosophy's greatest deception. We unpack why doubt itself is the ultimate illusion, how knowledge is primitive instant recognition, and what this means for self, free will & consciousness. As a listener of TOE you can get a special 20% off discount to The Economist and all it has to offer! Visit https://www.economist.com/toe Join My New Substack (Personal Writings): https://curtjaimungal.substack.com Timestamps: 00:00 Introduction 01:28 The Nature of Knowledge 10:58 Philosophers and the Skeptical Mindset 16:57 Types of Skepticism 22:27 Exploring Knowledge Attribution 29:51 The Illusion of Knowledge 34:16 Knowing Without Knowing 38:10 Writing About Knowledge 46:10 Analyzing Knowledge 55:08 The Gettier Problem and Its Challenges 1:01:10 The Functionality of Knowledge 1:11:23 Collaborative Understanding of Knowledge 2:10:00 Understanding and Consciousness 2:26:32 Truth and Its Nature 2:32:16 Superposition and Contradictions 2:32:19 Conclusion Listen on Spotify: https://tinyurl.com/SpotifyTOE Become a YouTube Member (Early Access Videos): https://www.youtube.com/channel/UCdWIQh9DGG6uhJk8eyIFl1w/join Links Mentioned: - Knowledge: A Very Short Introduction (book): https://www.amazon.com/Knowledge-Very-Short-Introduction-Introductions/dp/019966126X - Knowledge and its Limits (book): https://www.amazon.ca/Knowledge-its-Limits-Timothy-Williamson/dp/019925656X - Very Short Introductions (series): https://www.google.com/search?q=a+very+short+introduction+to+series&sca_esv=3da4db664be6b3a1&ei=ypX6Z6flHsDniLMP2v2QkQk&ved=0ahUKEwin8oSB9tKMAxXAM2IAHdo-JJIQ4dUDCBA&uact=5&oq=a+very+short+introduction+to+series&gs_lp=Egxnd3Mtd2l6LXNlcnAiI2EgdmVyeSBzaG9ydCBpbnRyb2R1Y3Rpb24gdG8gc2VyaWVzMgUQABiABDILEAAYgAQYhgMYigUyCxAAGIAEGIYDGIoFMgsQABiABBiGAxiKBTIIEAAYogQYiQUyCBAAGIAEGKIEMggQABiABBiiBDIFEAAY7wVIqBRQxAtYwBBwAXgAkAEAmAFZoAGtAqoBATS4AQPIAQD4AQGYAgSgAocCwgIKEAAYsAMY1gQYR8ICDRAuGIAEGLADGEMYigXCAg0QABiABBiwAxhDGIoFwgIPEAAYgAQYQxiKBRhGGPsBwgIbEAAYgAQYQxiKBRhGGPsBGJcFGIwFGN0E2AEBwgIGEAAYBxgemAMAiAYBkAYKugYGCAEQARgTkgcBNKAHph6yBwEzuAf_AQ&sclient=gws-wiz-serp#wgvs=e - Time: A Very Short Introduction (book): https://www.amazon.ca/Time-Short-Introduction-Jenann-Ismael/dp/0198832664 - Laplace meets Godel: https://www.youtube.com/watch?v=ZB3tS7j7nNU - Flexible Goals (paper): https://onlinelibrary.wiley.com/doi/pdf/10.1111/cogs.13195 - The Legend of the Justified True Belief Analysis (paper): https://philpapers.org/archive/DUTTLO-3.pdf - Lay Denial of Knowledge for Justified True Beliefs (paper): https://philpapers.org/archive/NAGLDO - TOE's Consciousness Iceberg: https://www.youtube.com/watch?v=GDjnEiys98o - Matt Segal on TOE: https://www.youtube.com/watch?v=DeTm4fSXpbM - Curt reads Plato's Cave: https://www.youtube.com/watch?v=PurNlwnxwfY - David Bentley Hart on TOE: https://www.youtube.com/watch?v=NEAgVvW9i10 - Donald Hoffman on TOE: https://www.youtube.com/watch?v=CmieNQH7Q4w&t=1s - Iain McGilchrist on TOE: https://www.youtube.com/watch?v=M-SgOwc6Pe4&t=6326s&ab_channel=CurtJaimungal - Geoffrey Hinton on TOE: https://www.youtube.com/watch?v=b_DUft-BdIE - John Vervaeke on TOE: https://www.youtube.com/watch?v=GVj1KYGyesI&t=1s - Wolfgang Smith on TOE: https://www.youtube.com/watch?v=vp18_L_y_30 - Polymath's Ai panel: https://www.youtube.com/watch?v=abzXzPBW4_s - Donald Hoffman and Philip Goff on TOE: https://www.youtube.com/watch?v=MmaIBxkqcT4 - Robert Sapolsky on TOE: https://www.youtube.com/watch?v=z0IqA1hYKY8&pp=ygUUY3VydCByb2JlcnQgc2Fwb2xza3k%3D - Curt debunks the “all possible paths” myth: https://www.youtube.com/watch?v=XcY3ZtgYis0&t=46s Support TOE on Patreon: https://patreon.com/curtjaimungal Twitter: https://twitter.com/TOEwithCurt Discord Invite: https://discord.com/invite/kBcnfNVwqs #science Learn more about your ad choices. Visit megaphone.fm/adchoices

Hosted by Chris Beckett & Shane Ludtke, two amateur astronomers in Saskatchewan. actualastronomy@gmail.com The Actual Astronomy Podcast presents A History of Planetary Motion. In this episode we are joined again by Dave Chapman. Dave will review the history of our understanding of planetary motion, from prehistoric times and antiquity to the present day. He covers the contributions of Mesopotamians, The Greeks, Copernicus, Brahe, Kepler, Galileo, Newton, Halley, Lagrange, Laplace, Gauss, Le Verrier, Galle, Einstein, and Bretagnon. He concludes that our knowledge has progressed immensely, but in a way, we have come full circle!   We've added a new way to donate to 365 Days of Astronomy to support editing, hosting, and production costs.  Just visit: https://www.patreon.com/365DaysOfAstronomy and donate as much as you can! Share the podcast with your friends and send the Patreon link to them too!  Every bit helps! Thank you! ------------------------------------ Do go visit http://www.redbubble.com/people/CosmoQuestX/shop for cool Astronomy Cast and CosmoQuest t-shirts, coffee mugs and other awesomeness! http://cosmoquest.org/Donate This show is made possible through your donations.  Thank you! (Haven't donated? It's not too late! Just click!) ------------------------------------ The 365 Days of Astronomy Podcast is produced by the Planetary Science Institute. http://www.psi.edu Visit us on the web at 365DaysOfAstronomy.org or email us at info@365DaysOfAstronomy.org.

On today's show Tom, Glenn, and Chris trace the theological heritage of historic Christian and Reformed moral theology as it drew upon and developed natural law thinking as one resource for moral wisdom and engagement with culture. As we address moral challenges of our age, we have a rich heritage in our faith, from the early Church through various Protestant and Reformed lines, to draw upon as we aim to unpack biblical ethical wisdom in our time. The natural law tradition is one such line which the Reformed line classically embraced and developed in light of its core theological insights. The pugs enjoy a lively conversation around this important contribution to moral theology. The Right Use of Moral Philosophy by Pierre de La Place: https://www.amazon.com/Philosophy-Sources-Modern-Economics-Ethics/dp/1949011062 Support the Pugcast on Patreon: https://www.patreon.com/thetheologypugcast?fbclid=IwAR17UHhfzjphO52C_kkZfursA_C784t0ldFix0wyB4fd-YOJpmOQ3dyqGf8

On today's show Tom, Glenn, and Chris trace the theological heritage of historic Christian and Reformed moral theology as it drew upon and developed natural law thinking as one resource for moral wisdom and engagement with culture. As we address moral challenges of our age, we have a rich heritage in our faith, from the early Church through various Protestant and Reformed lines, to draw upon as we aim to unpack biblical ethical wisdom in our time. The natural law tradition is one such line which the Reformed line classically embraced and developed in light of its core theological insights. The pugs enjoy a lively conversation around this important contribution to moral theology.The Right Use of Moral Philosophy by Pierre de La Place: https://www.amazon.com/Philosophy-Sources-Modern-Economics-Ethics/dp/1949011062Support the Pugcast on Patreon: https://www.patreon.com/thetheologypugcast?fbclid=IwAR17UHhfzjphO52C_kkZfursA_C784t0ldFix0wyB4fd-YOJpmOQ3dyqGf8